Full Analysis
Clinical Trial
Can a diabetes drug slow cognitive decline in Alzheimer's disease?
Original title: Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial
Sample Size
204 participants
Study Type
Clinical Trial
Duration
52 weeks
Overview
In Plain Language
Liraglutide showed no effect on brain glucose metabolism but improved executive function scores compared to placebo in Alzheimer's patients.
Clinical trial204 participants
The Numbers
Effect sizes:
- Cerebral glucose metabolism difference = −0.17
- ADAS-Exec difference = 0.15
- ADCS-ADL difference = −0.58
- CDR-SoB difference = −0.06
Only relative risk is reported. Without absolute risk numbers, a "22% increase" could mean going from 5% to 6.1% — a small real-world change.